Literature DB >> 24907903

Cerebrospinal fluid CXCL13 is a prognostic marker for aseptic meningitis.

Juichi Fujimori1, Ichiro Nakashima2, Hiroshi Kuroda2, Kazuo Fujihara3, Masashi Aoki2.   

Abstract

In exceptional cases, patients with aseptic meningitis eventually develop aseptic meningoencephalitis. To find a candidate marker for the development of aseptic meningoencephalitis in adult patients diagnosed with aseptic meningitis, we compared 12 different cytokines/chemokines in cerebrospinal fluid (CSF) from 5 patients with aseptic meningoencephalitis, 8 patients with aseptic meningitis, and 8 patients with control disease. Only the CXCL13 concentration was significantly elevated in the CSF of the group with aseptic meningoencephalitis compared with the group with aseptic meningitis. Thus, CSF CXCL13 may be a useful marker for predicting the prognosis of aseptic meningitis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aseptic meningitis; Aseptic meningoencephalitis; CXCL13; Cerebrospinal fluid (CSF); Chemokine; Cytokine

Mesh:

Substances:

Year:  2014        PMID: 24907903     DOI: 10.1016/j.jneuroim.2014.05.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

Review 1.  Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Authors:  Juan Carlos Garcia-Monco; Jorge L Benach
Journal:  Ann Neurol       Date:  2019-01       Impact factor: 10.422

2.  Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis.

Authors:  Zhaojun Duan; Jian Gao; Ling Zhang; Hua Liang; Xiangbo Huang; Qiang Xu; Yu Zhang; Tao Shen; Fengmin Lu
Journal:  Oncotarget       Date:  2015-12-29

3.  Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.

Authors:  Masahiro Maeyama; Takashi Sasayama; Kazuhiro Tanaka; Satoshi Nakamizo; Hirotomo Tanaka; Masamitsu Nishihara; Yuichi Fujita; Kenji Sekiguchi; Masaaki Kohta; Katsu Mizukawa; Takanori Hirose; Tomoo Itoh; Eiji Kohmura
Journal:  Cancer Med       Date:  2020-04-20       Impact factor: 4.452

4.  Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases.

Authors:  Gildas Lepennetier; Zsuzsanna Hracsko; Marina Unger; Martijn Van Griensven; Verena Grummel; Markus Krumbholz; Achim Berthele; Bernhard Hemmer; Markus C Kowarik
Journal:  J Neuroinflammation       Date:  2019-11-14       Impact factor: 8.322

5.  CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients.

Authors:  Xue-Wu Liu; Sheng-Jun Wang; You-Ting Lin; Xue Yang; Jing-Wei Lv
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-11       Impact factor: 2.570

6.  Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.

Authors:  Georg Pilz; Irma Sakic; Peter Wipfler; Jörg Kraus; Elisabeth Haschke-Becher; Wolfgang Hitzl; Eugen Trinka; Andrea Harrer
Journal:  Fluids Barriers CNS       Date:  2020-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.